检索结果-南通市图书馆

Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?

World Journal of Clinical Oncology 2021年第1期12卷 1-5页

作者： Jose Maximo Barros Manglio miguel rizzo Jorge Oscar Chiozza Felipe Counago Department of Radiation Oncology Radiotherapy CenterHospital Universitario AustralVidt Oncologia RadianteCABA 1425Argentina Department of Medical Oncology Hospital Universitario AustralBuenos Aires 1629Argentina Department of Radiation Oncology Hospital Universitario Quirónsalud MadridHospital La LuzUniversidad Europea de MadridMadrid 28028Spain

Thoracic radiotherapy(TRT)is one of the main treatments in limited-stage small cell lung cancer(LS-SCLC).Hyperfractionated TRT(45 Gy,1.5 Gy twice daily)has been the standard of care(SOC)since Turrisi and colleagues published the results of their clinical trial in *** meta-analyses have demonstrated the benefits of concurrent chemotherapy and TRT in terms of intrathoracic disease control at 2 years and 3-year overall survival(OS).The phase 2 trial by Grønberg et al(2016)comparing once-daily hypofractionated TRT to twice-daily hyperfractionated TRT in LS-SCLC found similar outcomes in both groups in terms of response rate,progression-free survival(PFS),grade 3-4 adverse effects,and *** CONVERT trial,published in 2017,failed to demonstrate the superiority of the conventional scheme(once-daily TRT)vs twice-daily radiotherapy,despite the application of modern radiotherapy techniques and a quality assurance programme,thus confirming the twice-daily hyperfractionated regimen as the *** the 2020 American Society of Clinical Oncology(ASCO)annual meeting,Grønberg et al reported preliminary findings from a phase 2 trial comparing two different TRT dose regimens(45 Gy vs 60 Gy),both administered twice *** data demonstrated a marked improvement in 2-year survival rates in the high dose arm(70.2%vs 46.1%,P=0.002),despite similar objective response rates and PFS *** findings provide a new treatment alternative to consider:Hyperfractionated,high-dose ***,the results of that trial will need to be validated in a large,randomized phase 3 *** results of the phase 2 CALCG 30610 trial will help to clarify the optimal dose and *** potential role of upfront immunotherapy,which early data suggest may improve OS,also needs to be determined.

关键词： Thoracic radiotherapy Limited-stage small cell lung cancer Hyperfractionated High dose American Society of Clinical Oncology Small cell lung cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immunotherapy and immunoescape in colorectal cancer

引用

World Journal of Gastroenterology 2007年第44期13卷 5822-5831页

作者： Guillermo Mazzolini Oihana Murillo Catalina Atorrasagasti Juan Dubrot Iigo Tirapu miguel rizzo Ainhoa Arina Carlos Alfaro Arantza Azpilicueta Carmen Berasain José L Perez-Gracia Alvaro Gonzalez Ignacio Melero Liver Unit Facultad de Ciencias Biomédicas Universidad Austral Presidente Perón 1500 (1635) Derqui-Pilar Buenos Aires Argentina Centro de Investigación Médica Aplicada and Clínica Universitaria Universidad de Navarra Pamplona Spain

Immunotherapy encompasses a variety of interventions and techniques with the common goal of eliciting tumor cell destructive immune responses. Colorectal carcinoma often presents as metastatic disease that impedes curative surgery. Novel strategies such as active immunization with dendritic cells (DCs), gene transfer of cytokines into tumor cells or administration of immunostimulatory monoclonal antibodies (such as anti-CD137 or anti-CTLA-4) have been assessed in preclinical studies and are at an early clinical development stage. Importantly, there is accumulating evidence that chemotherapy and immunotherapy can be combined in the treatment of some cases with colorectal cancer, with synergistic potentiation as a result of antigens cross-presented by dendritic cells and/or elimination of competitor or suppressive T lymphocyte populations (regulatory T-cells). However, genetic and epigenetic unstable carcinoma cells frequently evolve mechanisms of immunoevasion that are the result of either loss of antigen presentation, or an active expression of immunosuppressive substances. Some of these actively immunosuppressive mechanisms are inducible by cytokines that signify the arrival of an effector immune response. For example, induction of 2, 3 indoleamine dioxygenase (IDO) by IFNγ in colorectal carcinoma cells. Combinational and balanced strategies fostering antigen presentation, T-cell costimulation and interference with immune regulatory mechanisms will probably take the stage in translational research in the treatment of colorectal carcinoma.

关键词： Colorectal carcinoma Immunotherapy Gene therapy interleukin-12 Dendritic cells CD137 indoleamine 2, 3 dioxygenase

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

First-line cisplatin,docetaxel,and cetuximab for patients with recurrent or metastatic head and neck cancer:A multicenter cohort study

引用

World Journal of Clinical Oncology 2022年第2期13卷 147-158页

作者： Agustin Falco Mariano Leiva Albano Blanco Guido Cefarelli Andres Rodriguez Juan Melo Federico Cayol Manglio miguel rizzo Alejandro Sola Hernan Rodriguez Montani Matias Chacon Diego Enrico Federico Waisberg Department of Medical Oncology Head and Neck UnitAlexander Fleming Cancer InstituteBuenos Aires 1428Argentina Department of Medical Oncology Alexander Fleming Cancer InstituteBuenos Aires 1426Argentina Department of Medical Oncology Hospital Italiano de Buenos AiresBuenos Aires 1199Argentina Department of Medical Oncology Hospital Universitario AustralPilar 1629Argentina Department of Medical Oncology Fundación Centro Oncológico de Integración RegionalMendoza 5500Argentina Department of Medical Oncology Hospital Italiano RosarioSanatorio de la MujerRosario 2001Argentina

BACKGROUND The targeted therapy cetuximab[directed at the epidermal growth factor receptor(EGFR)]in combination with 5-fluorouracil and platinum-based chemotherapy(the EXTREME regimen)has shown substantial efficacy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck(R/M SCCHN).Thus,this scheme has been established as the preferred first-line option for these ***,more recently,a new strategy combining platinum,taxanes,and cetuximab(the TPEx regimen)has demonstrated similar efficacy with a more favorable toxicity profile in clinical *** To evaluate the safety and efficacy of the TPEx scheme as first-line therapy in advanced SCCHN in a multicenter cohort *** This retrospective multicenter cohort study included patients with histologically confirmed recurrent or metastatic SCCHN treated with first-line TPEx at five medical centers in Argentina between January 1,2017 and April 31,*** consisted of four cycles of docetaxel,cisplatin,and cetuximab followed by cetuximab maintenance *** outcomes and toxicity profiles were collected from medical *** response was assessed by the investigator in accordance with Response Evaluation Criteria in Solid Tumors(version 1.1).Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events(version 4.0).RESULTS Twenty-four patients were *** median age at diagnosis was 58 years(range:36-77 years).The majority of patients(83.3%)received at least four chemotherapy cycles in the initial *** the included group,the overall response rate was 62.5%,and 3 patients achieved a complete response(12.5%).The median time to response was 2.4 mo[95% confidence interval(CI):1.3-3.5].With a median follow-up of 12.7 mo(95%CI:8.8-16.6),the median progression-free survival(PFS)was 6.9 mo(95%CI:6.5-7.3),and the overall survival rate at 12 mo was 82.4%.Patients with documented tumor response s

关键词： Recurrent and/or metastatic head and neck cancer TPEx schema Cetuximab Docetaxel Cisplatin First-line

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：